Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05714657 · ClinicalTrials.gov registry record · Phase 2

Shortened Course Adjuvant Radiotherapy Following TORS

A Phase 2 study of HPV-Associated Oropharyngeal Squamous Cell Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.

Active
Registry status
Phase 2
Development phase
104
Enrollment target
3
Study locations

NCT05714657 is a Phase 2 study of HPV-Associated Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 104 participants. The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05714657, a Phase 2 study of HPV-Associated Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
104 participants
Enrollment target
3
Study locations

Study Summary

This is a single-arm, phase II study to establish the safety of reducing radiation dose in selected HPV-Associated OPSCC patients receiving adjuvant radiation after TORS and neck dissection. This protocol also allows for sparing of the primary resection bed, in appropriate patients, as previously published by our group and found to be safe and effective.

Interventions

  • RADIATION Shortened Course Adjuvant Radiotherapy Following TORS

Study Locations (3)

Pennsylvania

  • Lancaster General Hospital - Lancaster
  • University of Pennsylvania - Philadelphia
  • Pennsylvania Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2023-01-30
Est. Completion 2026-04-30
Phase Phase 2

What the Registry Record Tells You About NCT05714657

The ClinicalTrials.gov registry entry for NCT05714657 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HPV-Associated Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Shortened Course Adjuvant Radiotherapy Following TORS is the first listed.

NCT05714657 reports 3 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05714657 about?

NCT05714657 is a clinical study titled "Shortened Course Adjuvant Radiotherapy Following TORS". This is a single-arm, phase II study to establish the safety of reducing radiation dose in selected HPV-Associated OPSCC patients receiving adjuvant radiation after TORS and neck dissection. This protocol also allows for sparing of the primary resection bed, in appropriate patients, as previously pu...

What is the current status of trial NCT05714657?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2023-01-30. Estimated completion is 2026-04-30.

What conditions does trial NCT05714657 study?

This clinical trial studies the following conditions: HPV-Associated Oropharyngeal Squamous Cell Carcinoma.

What interventions are being tested in trial NCT05714657?

The interventions under investigation include: Shortened Course Adjuvant Radiotherapy Following TORS (RADIATION).

Who is sponsoring clinical trial NCT05714657?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05714657 being conducted?

This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.